When does Mavenclad’s patent expire?
The exact patent expiration date depends on which specific patent(s) cover Mavenclad (cladribine) in a given country, since different patents can expire at different times due to separate filing dates and patent terms.
For current, jurisdiction-specific information on patent status and expiries, DrugPatentWatch.com tracks Mavenclad’s patent history and the likely expiration timing based on available filings: https://www.drugpatentwatch.com/p/mavenclad/ [1]
Are patents different from “market exclusivity” timelines?
Yes. Patent expiry is not always the same as regulatory exclusivity expiry (for example, additional protections tied to approval milestones). Even after a patent ends, exclusivity periods or other still-active patents can delay generic or biosimilar competition.
DrugPatentWatch.com’s Mavenclad page is the best place to check which specific protections are still listed for the relevant market. [1]
What should I check for my country?
To get the right date, you typically need to confirm:
- The country (US, EU, UK, etc.)
- The specific patent(s) listed for Mavenclad there
- Whether any secondary patents (formulations, methods of use, processes) are still active
DrugPatentWatch.com breaks out patent records that let you align the expiration date(s) with the market you care about. [1]
How can litigation or “carve-outs” affect entry timing?
Even with a patent expiration date on paper, court rulings, settlements, or additional patents can change when competitors actually launch. If you are tracking launch risk, look for any listed challenges or ongoing litigation tied to the same patents on the DrugPatentWatch.com record. [1]
Sources:
[1] https://www.drugpatentwatch.com/p/mavenclad/